Biogroup (BIOGRP) EUR1.05bn (up from EUR1bn) 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law. Settles 02/09. New term loan size reduced by EUR50m to EUR1.45bn.
- CAB EUR800m (up from EUR750m) sr sec notes due 02/01/28 (7y). NC3 (MWC B+50bp), then at 101.688, 100.844, 100. Equity claw: 3y 40% at 103.375. Special call: 10% per year the 1st 3 years at 103. B2/B-/B+ (negative/stable/stable). IPT mid to high 3s. Px talk: 3.25%-3.50%. Final terms: EUR800m at 3.375%. Priced:3.375% at 100. +409bp vs DBR 0.5% 02/15/28.
- Laboratoire Eimer EUR250m sr notes due 02/01/29 (8y). NC3 (MWC B+50bp), then at 102.50, 101.25, 100. Equity claw: 3y 40% at 105.00. Caa1/CCC/CCC+ (negative/stable/stable). Reg S ISIN: XS2294187690. IPT mid 5s. Px talk: 5.00%-5.25%. Final terms: EUR250m at 5.00%. Priced: 5.00% at 100. +567bp vs DBR 0.25% 02/15/29.
Did investor call at 10am UKT 01/25. Virtual meetings available through 01/27. Books closed at 10am UKT 01/28. UOP: along with a new EUR1.45bn (down from EUR1.5bn) term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.